Osteonecrosis - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 42 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Osteonecrosis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Osteonecrosis - Pipeline Review, H2 2014', provides an overview of the Osteonecrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Osteonecrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteonecrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Osteonecrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Osteonecrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Osteonecrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Osteonecrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Osteonecrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Osteonecrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Osteonecrosis Overview 6
Therapeutics Development 7
Pipeline Products for Osteonecrosis - Overview 7
Pipeline Products for Osteonecrosis - Comparative Analysis 8
Osteonecrosis - Therapeutics under Development by Companies 9
Osteonecrosis - Therapeutics under Investigation by Universities/Institutes 10
Osteonecrosis - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Osteonecrosis - Products under Development by Companies 14
Osteonecrosis - Products under Investigation by Universities/Institutes 15
Osteonecrosis - Companies Involved in Therapeutics Development 16
Aprogen, Inc. 16
Bone Therapeutics SA 17
Enzo Biochem, Inc. 18
K-Stemcell Co., Ltd. 19
Osteonecrosis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
AP-102 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
LWnt-3a - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
PREOB - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecule to Agonize LRP for Osteonecrosis Of Jaws - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Stem Cell Therapy - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Osteonecrosis - Recent Pipeline Updates 35
Osteonecrosis - Dormant Projects 37
Osteonecrosis - Product Development Milestones 38
Featured News & Press Releases 38
Dec 04, 2014: Bone Therapeutics Authorised to Enrol Patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB 38
Nov 07, 2013: Bone Therapeutics' pivotal phase III osteonecrosis trial with PREOB hits a new milestone 38
Jan 28, 2013: Bone Therapeutics Raises �1.6m In Grant Subsidies From SRIW And Sambrinvest For Autologous Bone Cell Therapy 39
Oct 15, 2012: Bone Therapeutics Receives Clearance For Pivotal Phase III Osteonecrosis Trial With Preob In Europe And Treats The First Patients In Study 39
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables
Number of Products under Development for Osteonecrosis, H2 2014 7
Number of Products under Development for Osteonecrosis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Osteonecrosis - Pipeline by Aprogen, Inc., H2 2014 16
Osteonecrosis - Pipeline by Bone Therapeutics SA, H2 2014 17
Osteonecrosis - Pipeline by Enzo Biochem, Inc., H2 2014 18
Osteonecrosis - Pipeline by K-Stemcell Co., Ltd., H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 26
Number of Products by Stage and Molecule Type, H2 2014 28
Osteonecrosis Therapeutics - Recent Pipeline Updates, H2 2014 35
Osteonecrosis - Dormant Projects, H2 2014 37